Tetraphase Pharmaceuticals (NASDAQ:TTPH) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02), Morningstar.com reports. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%. The business had revenue of $1.15 million for the quarter, compared to analysts’ expectations of $2.09 million.
TTPH traded down $0.08 during trading hours on Friday, hitting $2.17. 808,354 shares of the company’s stock were exchanged, compared to its average volume of 678,728. Tetraphase Pharmaceuticals has a 12-month low of $2.01 and a 12-month high of $6.97. The company has a market cap of $118.93 million, a P/E ratio of -0.83 and a beta of 2.67.
Several equities research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Friday, August 3rd. B. Riley upped their target price on shares of Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, August 28th. ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 30th. Finally, HC Wainwright upped their target price on shares of Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, August 28th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $6.16.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Featured Article: What does earnings per share mean?
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.